by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
15/10/2024
September 2024 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Slow IPO season may be coming to an end, as four biotechs completed IPO of $100+ million
A slow season for biotech IPOs may be coming to an end. In September, four biopharmas have completed NASDAQ listings in which each raised more than $100 million, including Bicara with $315 million IPO. Most recently, Upstream Bio filed for IPO seeking to raise $100 million.
Antibody-Drug Conjugates
Patritumab-Dx demonstrates a statistically significant Ph 3 PFS improvement in NSCLC
The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated NSCLC who received prior EGFR TKI treatment met its primary endpoint of PFS, demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
Interleukin-15 and Interleukin-2
ImmunityBio presented positive long-term OS data of Anktiva in NSCLC
ImmunityBio announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced NSCLC being treated with checkpoint inhibitors.
Cell Therapies
ArsenalBio announced $325 million financing to advance cell therapy programs
Arsenal Biosciences, a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round.
Other Innovative Treatment Areas
Rybrevant plus chemotherapy show 49 % ORR in metastatic colorectal cancer
JNJ announced new data from the Phase 1b/2 OrigAMI-1 study, which showed Rybrevant (amivantamab-vmjw) combined with chemotherapy demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type metastatic CRC who have not previously received anti-EGFR therapy.
Sdílet na sociálních sítích